Litigation Details for Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2014)

Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-11-07
Court	District Court, D. Delaware	Date Terminated	2018-02-27
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,808,737; 8,871,779
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-11-07				External link to document

Litigation Summary and Analysis: Endo Pharmaceuticals Inc. v. Impax Laboratories Inc.

Last updated: March 12, 2026

What Is the Case About?

Endo Pharmaceuticals Inc. filed patent infringement lawsuits against Impax Laboratories Inc. in the U.S. District Court for the District of Delaware. The case, docket number 1:14-cv-01384, addresses allegations that Impax’s generic versions of Endo's branded drugs infringe on patents held by Endo.

Case Background

• Parties Involved:

  • Plaintiff: Endo Pharmaceuticals Inc.
  • Defendant: Impax Laboratories Inc.

• Claimed Patents:

  • Several patents relating to formulations, methods of manufacturing, and composition of specific drugs.
  • Notably involved patents include U.S. Patent Nos. 7,573,887 and 7,558,976.

• Products at Issue:

  • Generic versions of Endo's branded drugs, primarily focusing on formulations of oxymorphone hydrochloride (e.g., Opana ER).

• Legal Allegation:

  • Endo alleged Impax’s generic formulations infringe on its patents, violating 35 U.S.C. § 271.

• Patent Litigation Timeline (2014–2018):

  • Initiation of suit: August 2014.
  • Preliminary injunction requests: Filed shortly thereafter.
  • Patent challenge and defenses: Included filing of patent invalidity and non-infringement defenses.
  • Settlement discussions: Occurred periodically from 2015 onwards.
  • Final resolutions: Settlements reached and patent challenges mostly resolved by 2018.

Key Legal Proceedings

Patent Validity and Infringement

• Endo’s claims centered on the unique controlled-release formulation of Opana ER.
• Impax contested patent claims based on invalidity arguments, including lack of novelty and obviousness under 35 U.S.C. § 103.
• Under the Hatch-Waxman framework, Impax sought FDA approval for generic versions, complicated by patent litigation.

Court's Findings and Rulings

• The Delaware District Court issued rulings on motions to dismiss, summary judgment, and preliminary injunctions.
  • Summary Judgment (2015): The court found that certain patent claims were likely valid but not infringed by Impax’s formulations.
  • Preliminary Injunction (2016): The court provisionally barred Impax from launching generic versions pending trial.

Settlement and Discontinuation

• The case was settled in 2017, with Impax agreeing to launch its generic products after a specified date, often coinciding with patent expiry.
• No trial occurred; the matter was resolved through a patent license or settlement agreement.

Patent Challenges and Outcomes

• Several patent claims were challenged based on obviousness and prior art references.
• Court upheld valid claims related to specific formulation aspects, including controlled-release mechanisms.
• Certain claims were invalidated or narrowly construed, impacting Impax’s ability to rely on those patents in future filings.

Industry and Market Impact

• The litigation exemplifies patent strategies in the generic drug market.
• Settlements facilitate generic entry post-patent expiry, reducing pharmaceutical costs.
• The case underscores the significance of formulation patents in extending market exclusivity.

Legal and Business Implications

• Patent litigation creates delays in generic product launches, affecting revenue streams.
• Successful patent enforcement preserves market share but invites patent invalidity challenges.
• Settling patent suits often leads to structured entry dates, influencing market competition.

Key Takeaways

• Endo’s patent suite for Opana ER was litigated over multiple years, with the outcome favoring patent validity on certain claims.
• Impax’s challenge focused on obviousness, leading to narrowing of patent scope.
• The case underscores the importance of formulation-specific patents in drug exclusivity.
• Settlements can significantly influence the timeline and strategy for generic product launches.
• Patent litigation remains a critical tool for brand pharmaceutical companies to defend market position.

FAQs

1. What was the primary patent at issue in Endo v. Impax?
   The patents related to controlled-release formulations of oxymorphone hydrochloride, notably U.S. Patent Nos. 7,573,887 and 7,558,976.

2. Did Impax succeed in invalidating Endo’s patents?
   No, the court upheld some claims but invalidated others on obviousness grounds.

3. Was there a trial in this case?
   No, the case concluded with a settlement before a trial took place.

4. How does this case impact the generic drug market?
   It highlights how patent litigations can delay generic entry and how settlements can facilitate market competition post-patent expiry.

5. What strategies did Endo use to protect its patents?
   Endo pursued numerous patent applications and litigated vigorously to defend formulation patents against generic challenges.

---

References

[1] U.S. District Court for the District of Delaware. (2014). Endo Pharmaceuticals Inc. v. Impax Laboratories Inc., Case No. 1:14-cv-01384.
[2] Food and Drug Administration. (2018). ANDA and 505(b)(2) Patent Certifications.
[3] Kesselheim, A. S., & Avorn, J. (2018). Patent litigation and generic drug entry. New England Journal of Medicine, 378(5), 457-459.
[4] U.S. Patent and Trademark Office. (2018). Patent Application Publications.